STEMON: REGISTRATION OF TELOMERE RESTORING EXOSOME “TELOMERE REPROSOME” IN ICID.

Republic of Korea – July 27, 2022 —

Bio-venture company, STEMON, [(CEO Soonhag Kim) (www.stemon.co.kr )] announced the registration of exosomes that restore telomere length in the International Cosmetic Ingredient Dictionary (ICID). It said to be the premier registration of a substance capable of telomere regeneration in the ICID.

The newly registered substance is TELOMERE REPROSOME, a customized exosome capable of telomere length restoration and regeneration, and is manufactured to induce exosomes containing telomerase (TERT) proteins using Entr (Ultrasound-directed permeation of Environmental transition-guided cellular reprogramming) technology, the source technology of STEMON’s digital cell reprogramming research.

Telomere is a region of repeating nucleotide sequences associated with specialized proteins at the end of each eukaryotic chromosome, and the telomeres-binding proteins protect the end of the chromosome. As cell division repeats, telomeres become shorter and eventually disappear, and as this phenomenon causes cell senescence, it serves as an indicator of aging. Particularly, as the telomeres shorten, there is increased possibility of aging-related diseases such as high blood pressure, metabolic syndrome, diabetes, and dementia, and so research focused on increasing their lengths in order to address this problem is currently in progress.

The cell’s “Telomeres” are regulated by a reverse transcription enzyme called “Telomerase”. However, there is little telomerase activity in somatic(body) cells in normal cases, and high activity is detected only in stem cells and precursor cells that require active division. Based on this, a method of restoring telomeres has not been developed. In the meantime, STEMON has confirmed that following Entr® treatment, Telomere Reprosome induced from human dermal fibroblasts possess telomerase protein.

Because the induced Telomere Reprosomes also contain a variety of anti-aging proteins, it was discovered that when the Telomere Reprosomes were treated into a cell, the endogenous telomerase activity increased, and through induction of increased telomere restoration by the existing length of telomeres at the end of cell’s chromosomes, and an increase in anti-aging activity was revealed.

A STEMON official stated; “This is a safe and ground-breaking telomere elongation technology that holds the promise of cell-life prolongation through the restoration of telomere length.” He added, “By treating skin fibroblasts with ultrasonic waves and the introduction of a medium for inducing telomerase protein, we have facilitated the induction of a customized reprosome “Telomere Reprosome” which has the ability to induce telomerase protein expression and telomere length restoration activity and with this as foundation of ICID registration, we hope to carry out various clinical activities and beauty business.”

In addition to completing ICID registration for “Telomere Reprosome”, STEMON, along with the acquisition of two domestic patents for the source technology of Telomere Reprosome Induction is also examining overseas patency in the United States, Europe, Japan and China.

STEMON stated “various customized reprosomes are currently striving to facilitate clinical progress in the areas of liver cirrhosis , lung fibrosis and atopic dermatitis in addition to develop a new concept of beauty care products.

Contact Info:
Name: Stemon
Email: Send Email
Organization: STEMON Inc.
Address: Room 1162 of B-dong, SKV1 Tower, Galmachi-ro 288beon-gil14 , Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Phone: 082-31-730-6227
Website: https://www.stemon.co.kr/

Release ID: 89079042

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.